Figure 4.
Neutralizing antibodies produced in plasma and BALF against SARS-CoV-2 variants. (A) Measurement of relative inhibition of ligand interaction between soluble ACE2 and Wuhan ancestral reference strain, Delta variant and Omicron variant spike protein by neutralizing antibodies in plasma at endpoint analyzed by snELISA. Reciprocal ID50 neutralizing titer of adjuvanted vaccine formulations in (B) plasma and (C) BALF blocking Wuhan reference strain (blue), Delta variant (red) and Omicron variant (purple) spike and ACE2 ligand interaction. This assay is representative of technical triplicates and presented as mean ± standard deviation.